Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S.E., Belser, A., Kalliontzi, K., Babb, J., Su, Z., Corby, P., Schmidt, B.L. (2016) Journal of Psychopharmacology , 30(12) , 1165-1180
Zusammenfassung
Double-blind, placebo-controlled, crossover trial with 29 cancer patients with anxiety and depression. Single-dose psilocybin produced immediate, substantial, and sustained improvements in anxiety and depression, with approximately 60-80% maintaining clinically significant reductions at follow-up.
Schlüsselwörter
psilocybincanceranxietydepressionpalliative careNYU
Klinische Forschung